Business Wire

Mentimeter Announces Expansion of New North American Headquarters in Toronto as Company Scales for Growth

Share

Mentimeter, the leading audience engagement platform, today announced the expansion of its North American headquarters based in Toronto, Canada, with the appointment of Tobias Porseurd to the role of North American General Manager. The news comes on the heels of the company’s successful Series C funding round in 2022, which aimed to support its growing organizational adoption in North America. Mentimeter reported a 281% year-over-year increase in customers and an 85% increase in revenues from the North American region in 2022. Currently, 30% of Mentimeter’s global customers are based in the U.S. and Canada.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005002/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Tobias Porseurd, North America General Manager at Mentimeter (Photo: Business Wire)

“Our substantial growth in North America signifies the staying power of Mentimeter as a post-pandemic workplace engagement tool that brings organizational value by powering better employee performance, productivity and informed decision-making,” said Johnny Warström, co-founder and CEO of Mentimeter. “We are thrilled that Tobias is leading our expansion efforts from Toronto as he brings proven success in scaling businesses that will allow our workforce to keep up with surging demand for our solution.”

To keep pace with rising demand, Mentimeter’s expansion is aimed at increasing headcount by 50%, led by Porseurd, who began his career at Mentimeter in May 2021 as the director of talent acquisition in Stockholm, Sweden. During that time, Porseurd was responsible for the strategic direction and management of the SaaS scale-up and ensuring Mentimeter continues to be a great place to work by helping attract employees to an inclusive, fun and collaborative environment. Through this role, Porseurd helped recruit over 100 employees in less than 12 months. Prior to joining Mentimeter, he was the co-founder and board member of Talent Eye, a talent recruitment company that provides solutions and interventions to employees. He has recently relocated to Toronto, Canada with his family.

“Mentimeter values creating meaningful connections with its customers, which begins with proximity,” said Porseurd. “As the North America General Manager, I intend to take a holistic approach to building and deepening North American customer relationships and empowering our client-base to create a positive, supportive and productive workforce. I’m also excited to expand our office by bringing in top talent in the area to provide our innovative offering across enterprises of all sizes as well as universities.”

About Mentimeter:

Mentimeter, a leading audience engagement platform, makes it easier to gather input and beautifully visualize it in real-time - transforming a passive audience into active contributors. Mentimeter is fundamentally changing the culture of presentations, lectures, and workshops in business and education from talking to listening. Whether on-site, remote, or hybrid, Mentimeter creates a unique, transparent, and engaging experience for everyone. Since launching in 2012, users have gathered opinions, questions, and thoughts through more than 35 million presentations utilizing the Mentimeter platform.

###

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Thomas Dawson, Communications Specialist at Mentimeter
Email: thomas.dawson@mentimeter.com
Telephone: +46791014262

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product8.6.2023 00:12:00 EEST | Press release

RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005794/en/ The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predict

IFF Names New President of Nourish and Introduces Leadership Structure Aligned to New Operating Model7.6.2023 23:18:00 EEST | Press release

IFF (NYSE: IFF) today announced that Yuvraj Arora, currently President, U.S. Categories for Kellogg North America, will join IFF as President, Nourish, effective June 19, 2023. Arora brings more than 25 years of multinational CPG experience to IFF’s Executive Leadership Team, mostly recently leading Kellogg’s $7 billion U.S. portfolio through a period of strong growth and portfolio transformation. IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy. The shift from its current divisional structure to three core end markets—Food and Beverage, Home and Personal Care, and Health—will provide greater customer intimacy and enhance cross-functional collaboration, allowing for enhanced execution, speed and streamlined delivery. IFF expects its new operating model to be in effect by the beginning of 2024. As President, Nourish, Arora, will lead IFF’s Food and Beverage categories when the operating

Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe7.6.2023 22:00:00 EEST | Press release

Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe. *** June 7, 2023 Dear Customers, Researchers and Friends of Vizgen: We are disappointed – though not surprised – that 10x has filed another lawsuit that attempts to undermine innovation, eliminate competition and intimidate both customers and industry peers. Although 10x’s UPC complaint is not yet available to us, we will keep you updated as we learn more. In the meantime, rest assured that we will vigorously defend our shared interests in all proceedings with the UPC, much like we have in the ongoing litigation in the U.S. District Court for the District of Delaware. In the Delaware case, we have gone on the offensive to assert our own countercla

Brenus Pharma announces its international Scientific Committee7.6.2023 19:00:00 EEST | Press release

Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee. This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer. The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field: Pr François GHIRINGHELLI MD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL 2, Dijon. (FR) Head of the Board Pr Ahmad AWADA MD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active m

Lunaphore and CST Partnership Advances Spatial Biology Research with Over 1,700 IHC-Validated Antibodies for Use on COMET™7.6.2023 17:00:00 EEST | Press release

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership to enable the use of CST® antibodies on the Lunaphore COMET™ platform, a scalable hyperplex imaging solution for fully automated spatial biology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005502/en/ CST is a trusted provider of high-quality, rigorously validated antibodies for immunohistochemistry (IHC) that can detect key proteins in a variety of disease states. This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET™, empowering researchers to develop antibody panels quickly and with confidence. With a comprehensive offering of primary rabbit and mous

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom